NCT01753557View on ClinicalTrials.gov

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Chronic Hepatitis C (CHC)
Interventions
DRUG

MP-424

MP-424: 750mg every 8 hours (q8h) for 12 weeks

DRUG

RBV

RBV: 600 - 1000 mg/day based on body weight for 24 weeks

DRUG

PEG-IFN alfa-2a

PEG-IFN alfa-2a: 180mcg/week for 24 weeks

Trial Locations (1)

213-8587

Toranomon Hospital, Kawasaki

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY